홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
RNAZ
#4268
TransCode Therapeutics, Inc. Common Stock
9.830
0
USD
+0.31%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+0.31%
월간 변동
+3.39%
6달 변화
+3.39%
년간 변동율
+3.39%
이전 종가
9.800
0
Open
9.750
0
Bid
9.830
0
Ask
9.833
0
Low
9.750
0
High
9.830
0
양
9
마켓
주식
헬스케어
RNAZ
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
18.69 K
833.62 K
833.62 K
833.68 K
916.97 K
—
Valuation ratios
Enterprise value
—
—
—
-897.27 K
7.02 M
—
Price to earnings ratio
—
—
—
-0.07
0.47
—
Price to sales ratio
—
—
—
1
0.61
—
Price to cash flow ratio
—
—
—
0
0.01
—
Price to book ratio
—
—
—
0.63
-0.12
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.59
-0.81
0.92
-0.52
-0.93
-1.34
Return on equity %
-1.41
2.93
1.18
-0.7
-3.41
0.01
Return on invested capital %
-1 819.69
-5 498.91
-6 115.37
-19.33 K
-7 293.21
-38.24 K
Gross margin %
100
100
100
100
100
400
Operating margin %
1 376.48
-2 231.58
11.66 K
8 889.03
14.23 K
32.55 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 475.63
-2 592.49
-44.5 K
9 005.63
15.15 K
-22.94 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
1.58
2.56
5.2
5.27
1.6
14.62
Inventory turnover
—
—
—
—
—
—
Asset turnover
-0.04
0.04
-0
-0
-0
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1 036.75
1 846.9
18
5.04
4.92
1 874.85
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
119.55
456.03
67.34
8.88
3.4
535.65
Net current asset value per share
227.31
557.72
75.72
9.89
5.7
649.03
Tangible book value per share
103.96
-158.73
59.75
7.37
1.71
-89.89
Working capital per share
83.6
339.78
61.16
8.01
2.14
411.09
Book value per share
103.96
-158.73
59.75
7.37
1.71
-89.89
뉴스
TransCode, 방광암 치료 플랫폼 기술 도입 계약 체결
TransCode licenses bladder cancer therapy platform from Unleash
TransCode Therapeutics, IND 수정안 제출 후 주가 급등
트랜스코드 테라퓨틱스, 뇌종양 연구 발표 후 주가 급등
TransCode Therapeutics stock soars after promising glioblastoma study
TransCode Therapeutics appoints Jack E. Stover to board of directors
암 치료제 2a상 임상시험 예정: TransCode, Quantum Leap 협력
TransCode and Quantum Leap to test cancer therapy in phase 2a trial
TransCode Therapeutics appoints Michel Janicot as development officer
트랜스코드 테라퓨틱스, 주주 승인 후 우선주 조건 변경
Transcode Therapeutics amends preferred stock terms following shareholder approval
TransCode reports positive safety data from TTX-MC138 phase 1a trial